| Ytd | -40.29% | |
| 1y | 9.06% |
| Open | 2.80 | Prev Close | 2.76 | Low | 2.80 | High | 2.90 | Mkt Cap | 290.21M |
| Vol | 17.13K | Avg Vol | 32.12K | EPS | -0.67 | P/E | -4.31 | Forward P/E | -2.07 |
| Beta | 3.20 | Short Ratio | 1.41 | Inst. Own | 16.65% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 2.95 | 200-d Avg | 3.72 | 1yr Est | 6.67 |
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of
NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDA
EMERYVILLE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Prolynx, a biotechnology company developing a
NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDA
NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASD
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASD
PARIS, June 03, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Dat
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS- NASDAQ
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDA
Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) Pivotal Phase 2 first interim analysis
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of
NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NAS
NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- Cellectis (or the “Company”) (Euronext Growth: ALCLS -
NEW YORK, 13 avr. 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), société
U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt ro
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of
Cellectis S.A. (CLLS) Q4 2025 Earnings Call Transcript
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NAS
Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday'
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Mo
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announce
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn
Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that i
Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 39.7% to $0.1143 in pre-market trading after
Gainers
On Tuesday, 647 companies set new 52-week lows.
On Monday, 369 companies set new 52-week lows.
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings
On Friday, 199 companies reached new 52-week lows.
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss a
Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earn
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnin
During Monday's session, 402 companies made new 52-week lows.